Eli Lilly Other Long-Term Assets 2010-2024 | LLY

Eli Lilly other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Eli Lilly other long-term assets for the quarter ending September 30, 2024 were $5.122B, a 4.27% increase year-over-year.
  • Eli Lilly other long-term assets for 2023 were $4.99B, a 15.05% increase from 2022.
  • Eli Lilly other long-term assets for 2022 were $4.337B, a 6.23% increase from 2021.
  • Eli Lilly other long-term assets for 2021 were $4.083B, a 17.47% increase from 2020.
Eli Lilly Annual Other Long-Term Assets
(Millions of US $)
2023 $4,990
2022 $4,337
2021 $4,083
2020 $3,475
2019 $2,871
2018 $1,825
2017 $1,708
2016 $1,914
2015 $2,221
2014 $7,204
2013 $2,213
2012 $2,533
2011 $2,493
2010 $1,622
2009 $1,921
Eli Lilly Quarterly Other Long-Term Assets
(Millions of US $)
2024-09-30 $5,122
2024-06-30 $4,904
2024-03-31 $4,708
2023-12-31 $4,990
2023-09-30 $4,912
2023-06-30 $4,672
2023-03-31 $4,488
2022-12-31 $4,337
2022-09-30 $4,536
2022-06-30 $4,472
2022-03-31 $4,285
2021-12-31 $4,083
2021-09-30 $3,710
2021-06-30 $3,639
2021-03-31 $3,756
2020-12-31 $3,475
2020-09-30 $3,079
2020-06-30 $3,080
2020-03-31 $3,045
2019-12-31 $2,871
2019-09-30 $2,194
2019-06-30 $2,052
2019-03-31 $1,963
2018-12-31 $1,825
2018-09-30 $2,009
2018-06-30 $1,777
2018-03-31 $1,747
2017-12-31 $1,708
2017-09-30 $2,198
2017-06-30 $2,061
2017-03-31 $2,020
2016-12-31 $1,914
2016-09-30 $2,279
2016-06-30 $2,150
2016-03-31 $2,245
2015-12-31 $2,221
2015-09-30 $2,890
2015-06-30 $2,701
2015-03-31 $2,489
2014-12-31 $7,204
2014-09-30 $2,339
2014-06-30 $2,441
2014-03-31 $2,339
2013-12-31 $2,213
2013-09-30 $1,321
2013-06-30 $1,880
2013-03-31 $2,096
2012-12-31 $2,533
2012-09-30 $2,388
2012-06-30 $2,195
2012-03-31 $2,093
2011-12-31 $2,493
2011-09-30 $2,216
2011-06-30 $1,977
2011-03-31 $1,743
2010-12-31 $1,622
2010-09-30 $2,129
2010-06-30 $2,372
2010-03-31 $1,828
2009-12-31 $1,921
2009-09-30 $2,173
2009-06-30 $2,373
2009-03-31 $2,665
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $692.744B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94